Lupin launches moxifloxacin ophthalmic solution

| Updated on February 14, 2020 Published on February 14, 2020

Lupin has launched moxifloxacin ophthalmic solution USP, 0.5%, having received approval from the United States Food and Drug Administration earlier. The product would be manufactured at Lupin's Pithampur (Unit-II) facility, it said. The solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms. Moxifloxacin Ophthalmic Solution had an annual sales of approximately $10 million in the US (IQVIA MAT December 2019). Shares of drug maker Lupin closed 2 per cent higher at ₹717.85 on the BSE.

Published on February 14, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.